Moyamoya Disease treatment resistance in adults
Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing or occlusion of the terminal portions of the internal carotid arteries and their main branches. This narrowing leads to the development of a fragile network of abnormal collateral vessels that attempt to compensate for decreased blood flow, producing a distinctive “puff of smoke” appearance on angiographic imaging—hence the name “moyamoya,” which means “hazy” or “puff of smoke” in Japanese. While often diagnosed in children, adults can also be affected, and their disease course can differ significantly.
In adults, moyamoya disease frequently presents with ischemic strokes, transient ischemic attacks (TIAs), or even hemorrhagic strokes due to the rupture of fragile collateral vessels. The treatment landscape for moyamoya primarily revolves around surgical revascularization procedures aimed at restoring adequate cerebral blood flow and preventing ischemic events. Common surgical options include direct bypass techniques, such as superficial temporal artery to middle cerebral artery (STA-MCA) bypass, and indirect methods like encephaloduroarteriosynangiosis (EDAS). These procedures promote the development of new collateral vessels, improving cerebral perfusion.
However, a subset of adult patients exhibits resistance to initial surgical interventions or experiences recurrent ischemic or hemorrhagic events despite revascularization. Treatment resistance in adult moyamoya disease can be multifactorial. For instance, critical factors include the extent of the arterial occlusion, the adequacy of collateral vessel formation, and underlying co-morbidities such as hypertension or diabetes, which can impair vascular remodeling. Additionally, some patients may have a more aggressive disease course, with rapid progression of arterial stenosis, making surgical outcomes less predictable.
Managing treatment resistance poses significant clinical challenges. One approach involves careful postoperative monitoring with advanced imaging modalities such as magnetic resonance angiography (MRA) or perfusion studies to evaluate cerebral blood flow and collateral development. If inadequate revascularization is detected, repeat or additional surgical interventions may be considered. For example, combining direct and indirect bypass techniques can sometimes enhance revascularization efficacy. In some cases, angioplasty or stenting of stenotic arteries has been attempted, although these are less common and often less effective due to the diffuse nature of the disease.
Medical management also plays a vital role. Ensuring optimal control of risk factors like hypertension, hyperlipidemia, and smoking cessation can help reduce further vascular damage. Antiplatelet agents, such as aspirin, are typically used to prevent thrombotic events, although their efficacy in preventing progression or treatment resistance remains uncertain. Emerging therapies, including pharmacological agents aimed at promoting angiogenesis or reducing inflammation, are under investigation but are not yet standard practice.
The complexity of moyamoya disease in adults underscores the importance of a multidisciplinary approach involving neurologists, neurosurgeons, radiologists, and rehabilitation specialists. Tailoring treatment plans to individual patient profiles, closely monitoring disease progression, and being prepared to adapt strategies—whether surgical or medical—are essential for optimizing outcomes. Despite challenges posed by treatment resistance, ongoing research into the pathophysiology and novel therapies holds promise for improving management in adult patients with moyamoya disease.